vTv Therapeutics Inc. 8-K

What Happened
vTv Therapeutics Inc. (VTVT) filed a Form 8‑K on May 13, 2026 announcing a prospectus supplement to increase the number of Class A common shares offered under its previously announced at‑the‑market (ATM) sales program to the full amount permitted under that program. The company also filed a legal opinion from Dechert LLP regarding the legality of the Class A common stock issuable under the ATM program and incorporated that opinion into its effective shelf registration statement on Form S‑3.

Key Details

• Date filed: May 13, 2026 (Form 8‑K).
• Action: Prospectus supplement increases shares available under the ATM Program to the full authorized amount under that program.
• Legal counsel: Dechert LLP legal opinion attached as Exhibit 5.1 and consent included (Exhibit 23.1) to be incorporated by reference into the Form S‑3 shelf registration.
• Purpose: Enables issuance of additional Class A common stock through the ATM program (sales into the market at prevailing prices).

Why It Matters
This move gives vTv greater flexibility to raise capital by selling shares into the market under its ATM program. For investors, that means the company has an on‑ramp to access public funding quickly at market prices, but it also creates potential for future dilution if shares are sold. The attached Dechert LLP opinion confirms the company’s legal basis to issue those shares under the shelf registration, which is a procedural legal step investors often watch before new share issuance. Monitor future 8‑Ks and prospectus notices for any actual sales, pricing, and use of proceeds.